Tech & Pharma
The Global CCS Institute will establish an office in Japan to expand its involvement with some of the region’s leading capture technology developers.
Hitachi, Ltd. announced this week that it has identified India as a fifth key management area.
Pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase IIb clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.
Dr. Reddy’s Laboratories announced this week the initiation of a Phase II study of DRL-17822 in patients with diagnosis of type II dyslipidemia.
Sanofi-Aventis Philippines Inc. and Multicare Pharmaceuticals have entered into a marketing and distribution agreement.
Two memorandums of understanding have been signed between the Canadian Government of Saskatchewan and Hitachi companies for research into nuclear medicine and safer nuclear technologies.
Takeda Pharma announced today that it has initiated Phase II clinical trials of TAK-385 in Japan for the treatment of endometriosis and uterine fibroids.
The State Food and Drug Administration has approved Simcere Pharmaceutical Group’s new anti-rheumatic drug, Iremod, used to treat symptoms of active rheumatic arthritis.
Vasomedical, Inc. has signed an agreement to purchase Life Enhancement Technology Limited and Biox Instruments.
Lexapro® – the most prescribed branded antidepressant in the world – has been launched in Japan by H. Lundbeck A/S and its partners, Mochiba and Mitsubishi Tanabe Pharma.